Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Gilead Sciences Inc GILD

Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. It is focused on the discovery, development and commercialization of medicines in areas of unmet medical need. Its portfolio of marketed products includes AmBisome, Atripla, Biktarvy, Cayston, Complera, Descovy, Descovy for PrEP, Emtriva, Epclusa, Eviplera, Genvoya, Harvoni, Hepcludex, Hepsera, Jyseleca, Letairis, Odefsey, Sovaldi, Stribild, Sunlenca, Tecartus, Trodelvy, Truvada, Truvada for PrEP, Tybost, Veklury, Vemlidy, Viread, Vosevi, Yescarta and Zydelig. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, and Domvanalimab and zimberelimab, and seladelpar. Seladelpar shall be used for the treatment of primary biliary cholangitis (PBC), including pruritus. The Company operates in more than 35 countries.


NDAQ:GILD - Post by User

Bullboard Posts
Comment by zabberon May 14, 2015 7:13pm
150 Views
Post# 23730565

RE:RE:Can anyone explain the $234 value on this $98 stock?

RE:RE:Can anyone explain the $234 value on this $98 stock?*$108 stock :D :D

Regret selling a bit yesterday at $106 but if she keep pushing I'll forget about it.

Nice volume EOD and, apparently, above the upper band could make for a nice breakout. Hopefully investors start to factor in the better than expected Japan results, recent CC, and whatever the ASCO news is worth.

We'll see how the overall market holds up I guess, as this was no doubt buoyed a bit by the rising tide as well. Last correction (October) this thing followed the market down and I believe S&P hit an all time high today. Who knows, maybe investors will buy into the whole "weather slowed down retail sales" bit and the bull will keep running. That said, some of the bigger guys have been calling for a gradual end to the rally and could see the "sell in May" this year...
Bullboard Posts